Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Trading Update

19 Feb 2013 07:00

RNS Number : 1437Y
Surgical Innovations Group PLC
19 February 2013
 



 

 

 

Surgical Innovations Group plc

("SI" or the "Company")

 

Trading Update

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), provides the following trading update for the financial year ended 31 December 2012.

 

SI saw substantially improved trading across both SI Brand and OEM segments in the second half of 2012, driven by increased product demand resulting in contracted orders for delivery in 2012 of £5.6m. This represents an 85% improvement on first half performance; however due to manufacturing capacity constraints at the existing Leeds facility and a delay in US regulatory approval in the final month of the year, £1m of these orders were recognised as revenue in the first week of the financial year ending 31 December 2013.

 

As a consequence total revenue reported for the 12 months to 31 December 2012 is now expected to be £7.6m (FY 2011: £7.6m).

 

Following the strategic decision to promote SI Branded products, which now represent 68% of overall revenues (FY 2011: 62%), gross margins are expected to have improved by three basis points to 50.3% (FY 2011: 47.3%). Adjusted EBITDA for the period is ahead of the previous year at £2.85m (2011: £2.8m).

 

SI ended the year with short term borrowings of £1.4m against bank facilities provided by HSBC of £2.0m.

 

Given the revenue recognition of £1m in January 2013, the current financial year has started well and provides a sound platform for the remainder of the current financial year.

 

The Company will announce its preliminary results for the year ended 31 December 2012 on Tuesday, 9 April 2013.

 

Graham Bowland, Chief Executive Officer, commented: "I am pleased with the strong sales performance that we've achieved in the second half of the year. There is no doubt that the manufacturing capacity constraints we experienced in the final quarter of 2012 justify the need for our proposed new facility part funded by the award of the £5m RGF."

 

- ENDS -

 

Enquiries:

 

Surgical Innovations Group plc

www.sigroupplc.com

Doug Liversidge, Non-Executive Chairman

Tel: +44 (0) 113 230 7597

Graham Bowland, Chief Executive Officer

graham.bowland@surginno.co.uk

 

 

Seymour Pierce Limited

www.seymourpierce.com

Mark Percy (Corporate Finance)

Tel: +44 (0) 20 7107 8000

David Banks (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303 or lianne.cawthorne@walbrookpr.com

 

Notes to Editors:

 

About Surgical Innovations Group plc

 

Surgical Innovations Group plc specialises in the design and manufacture of creative solutions for minimally invasive surgery (MIS) and industrial markets.

 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

 

Over 120 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

 

The Group's patented products are sold through three main channels:

 

SI brand

Through an established network of distribution partners, Surgical Innovations branded products are sold in major medical markets including North America, Britain, South East Asia, Australasia and the Indian subcontinent.

 

OEM and IP

The Group supplies large medical device companies on an OEM basis, generating both sales and IP royalty fees. Clients include Teleflex Medical, Olympus and CareFusion.

 

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.

 

For more information, see www.sigrouplplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFLDFLITLIV
Date   Source Headline
27th Sep 20193:40 pmRNSExercise of Options, Issue of Equity and TVR
17th Sep 20197:00 amRNSHalf-year Report
3rd Sep 20197:00 amRNSNotice of Results
19th Jun 20194:03 pmRNSResult of AGM
19th Jun 20197:00 amRNSBoard and management structure changes
7th Jun 20197:00 amRNSTrading Update
6th Jun 20192:00 pmRNSHolding(s) in Company
29th May 20193:06 pmRNSExercise of Options, PDMR Shareholding & TVR
23rd May 201910:38 amRNSHolding(s) in Company
22nd May 201910:16 amRNSHolding(s) in Company
13th May 20196:25 pmRNSNotification of Major Interest in Shares
27th Mar 20197:00 amRNSGrant of Options
15th Mar 20194:27 pmRNSDirector/PDMR Shareholding
12th Mar 20197:00 amRNSFinal Results
28th Feb 20196:18 pmRNSExercise of Options & Total Voting Rights
28th Feb 20197:00 amRNSAppointment of CEO & changes in senior management
27th Feb 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUpdate on contingency planning for no-deal Brexit
14th Jan 20197:00 amRNSYear-end Trading Update
3rd Dec 20187:00 amRNSAppointment of Nominated Adviser and Broker
6th Nov 20187:00 amRNSSurgical robot technology UK distribution deal
16th Oct 201810:53 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSCE mark certification obtained for CELLIS range
11th Sep 201810:23 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSHalf-year Report
29th Aug 20187:00 amRNSCE mark validation indicated for CELLIS range
22nd Aug 20187:00 amRNSNotice of Results
26th Jun 20184:41 pmRNSResult of AGM
26th Jun 20187:00 amRNSAGM Statement
4th Jun 201811:34 amRNSHolding(s) in Company
25th May 20187:00 amRNSTrading Update
23rd Mar 20183:25 pmRNSDirector/PDMR Shareholding
13th Mar 20183:06 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
28th Feb 20187:00 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:01 amRNSDistribution agreement via Elemental Healthcare
19th Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSYear-end trading update
21st Dec 201712:15 pmRNSIssue of Shares
15th Nov 201711:47 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSDirector/PDMR Shareholding
31st Oct 201710:58 amRNSDirector/PDMR Shareholding
31st Oct 20177:00 amRNSGrant of Options
30th Oct 20172:33 pmRNSIssue of Equity
10th Oct 20173:36 pmRNSIssue of Equity
26th Sep 201712:28 pmRNSIssue of Equity
22nd Sep 20178:55 amRNSHolding(s) in Company
13th Sep 20177:00 amRNSHalf-year Report
10th Aug 20177:00 amRNSNotice of Results
4th Aug 201712:32 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.